Trial Profile
Phase I study of HC-1119, an androgen receptor inhibitor for the treatment of prostate cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Deutenzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology